Author: Antoinette R. Tan
Publisher: Springer
ISBN: 3319699806
Category : Medical
Languages : en
Pages : 187
Book Description
This guide provides practical information that will assist clinicians involved in the diagnosis, assessment, treatment, and follow-up care of patients with triple-negative breast cancer. After opening chapters on the pathologic evaluation, clinical presentation, genetics, and imaging features, the full range of current treatment approaches is thoroughly reviewed from a multidisciplinary perspective. Readers will find up-to-date information and guidance on surgical management, radiation therapy, tailored adjuvant therapy, neoadjuvant treatment, systemic treatment for metastatic disease, molecular profiling, and targeted therapy. The coverage is completed by discussion of special issues in young women with triple-negative breast cancer and individualization of the management approach in older patients affected with the disease. All healthcare professionals who care for patients with triple-negative breast cancer will find the book to be an invaluable source of expert advice on the issues faced in real-world practice.
Triple-Negative Breast Cancer
Author: Antoinette R. Tan
Publisher: Springer
ISBN: 3319699806
Category : Medical
Languages : en
Pages : 187
Book Description
This guide provides practical information that will assist clinicians involved in the diagnosis, assessment, treatment, and follow-up care of patients with triple-negative breast cancer. After opening chapters on the pathologic evaluation, clinical presentation, genetics, and imaging features, the full range of current treatment approaches is thoroughly reviewed from a multidisciplinary perspective. Readers will find up-to-date information and guidance on surgical management, radiation therapy, tailored adjuvant therapy, neoadjuvant treatment, systemic treatment for metastatic disease, molecular profiling, and targeted therapy. The coverage is completed by discussion of special issues in young women with triple-negative breast cancer and individualization of the management approach in older patients affected with the disease. All healthcare professionals who care for patients with triple-negative breast cancer will find the book to be an invaluable source of expert advice on the issues faced in real-world practice.
Publisher: Springer
ISBN: 3319699806
Category : Medical
Languages : en
Pages : 187
Book Description
This guide provides practical information that will assist clinicians involved in the diagnosis, assessment, treatment, and follow-up care of patients with triple-negative breast cancer. After opening chapters on the pathologic evaluation, clinical presentation, genetics, and imaging features, the full range of current treatment approaches is thoroughly reviewed from a multidisciplinary perspective. Readers will find up-to-date information and guidance on surgical management, radiation therapy, tailored adjuvant therapy, neoadjuvant treatment, systemic treatment for metastatic disease, molecular profiling, and targeted therapy. The coverage is completed by discussion of special issues in young women with triple-negative breast cancer and individualization of the management approach in older patients affected with the disease. All healthcare professionals who care for patients with triple-negative breast cancer will find the book to be an invaluable source of expert advice on the issues faced in real-world practice.
New Prognostic and Predictive Markers in Cancer Progression
Author: Susan Costantini Alfredo Budillon
Publisher: MDPI
ISBN: 3039439774
Category : Medical
Languages : en
Pages : 294
Book Description
Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient’s outcome and cancer recurrence probability after initial interventions such as surgery or drug treatments and, hence, to select follow-up and further treatment strategies. On the other hand, predictive markers are increasingly being used to evaluate the probability of benefit from clinical intervention(s), driving personalized medicine. Evolving technologies and the increasing availability of “multiomics” data are leading to the selection of numerous potential biomarkers, based on DNA, RNA, miRNA, protein, and metabolic alterations within cancer cells or tumor microenvironment, that may be combined with clinical and pathological data to greatly improve the prediction of both cancer progression and therapeutic treatment responses. However, in recent years, few biomarkers have progressed from discovery to become validated tools to be used in clinical practice. This Special Issue comprises eight review articles and five original studies on novel potential prognostic and predictive markers for different cancer types.
Publisher: MDPI
ISBN: 3039439774
Category : Medical
Languages : en
Pages : 294
Book Description
Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient’s outcome and cancer recurrence probability after initial interventions such as surgery or drug treatments and, hence, to select follow-up and further treatment strategies. On the other hand, predictive markers are increasingly being used to evaluate the probability of benefit from clinical intervention(s), driving personalized medicine. Evolving technologies and the increasing availability of “multiomics” data are leading to the selection of numerous potential biomarkers, based on DNA, RNA, miRNA, protein, and metabolic alterations within cancer cells or tumor microenvironment, that may be combined with clinical and pathological data to greatly improve the prediction of both cancer progression and therapeutic treatment responses. However, in recent years, few biomarkers have progressed from discovery to become validated tools to be used in clinical practice. This Special Issue comprises eight review articles and five original studies on novel potential prognostic and predictive markers for different cancer types.
Combinational Therapy in Triple Negative Breast Cancer
Author: Manzoor Ahmad Mir
Publisher: Academic Press
ISBN: 0323961371
Category : Science
Languages : en
Pages : 262
Book Description
Combinational Therapy in Triple Negative Breast Cancer discusses TNBC at the molecular level from a holistic approach, focusing on combinational strategies targeting various pathways involved in this specific cancer type. Using a monotherapy for the treatment of cancer, especially high-grade tumors like TNBC, is mostly worthless due to the inherent genetic instability of tumor cells to develop intrinsic and acquired resistance. Combination therapy presents more, or at least the same, effectiveness with lower doses of every single agent and decreases the likelihood of chemoresistance, making it essential to understand for multiple therapy options. The book is a valuable resource for cancer researchers, oncologists, graduate students and members of the biomedical field who are interested in the potential of combinational therapies to treat triple negative breast cancer. - Presents up-to-date and cutting-edge knowledge of Triple negative breast cancer (TNBC) biology, clinical aspects and treatment options - Discusses novel targets and pathways involved in TNBC - Provides insights and approaches for future research on TNBC
Publisher: Academic Press
ISBN: 0323961371
Category : Science
Languages : en
Pages : 262
Book Description
Combinational Therapy in Triple Negative Breast Cancer discusses TNBC at the molecular level from a holistic approach, focusing on combinational strategies targeting various pathways involved in this specific cancer type. Using a monotherapy for the treatment of cancer, especially high-grade tumors like TNBC, is mostly worthless due to the inherent genetic instability of tumor cells to develop intrinsic and acquired resistance. Combination therapy presents more, or at least the same, effectiveness with lower doses of every single agent and decreases the likelihood of chemoresistance, making it essential to understand for multiple therapy options. The book is a valuable resource for cancer researchers, oncologists, graduate students and members of the biomedical field who are interested in the potential of combinational therapies to treat triple negative breast cancer. - Presents up-to-date and cutting-edge knowledge of Triple negative breast cancer (TNBC) biology, clinical aspects and treatment options - Discusses novel targets and pathways involved in TNBC - Provides insights and approaches for future research on TNBC
Biomarkers in Breast Cancer
Author: Giampietro Gasparini
Publisher: Springer Science & Business Media
ISBN: 159259915X
Category : Medical
Languages : en
Pages : 335
Book Description
Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers.
Publisher: Springer Science & Business Media
ISBN: 159259915X
Category : Medical
Languages : en
Pages : 335
Book Description
Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers.
Innovations for Next-Generation Antibody-Drug Conjugates
Author: Marc Damelin
Publisher: Springer
ISBN: 3319781545
Category : Medical
Languages : en
Pages : 358
Book Description
Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.
Publisher: Springer
ISBN: 3319781545
Category : Medical
Languages : en
Pages : 358
Book Description
Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.
Cancer: New Insights for the Healthcare Professional: 2011 Edition
Author:
Publisher: ScholarlyEditions
ISBN: 1464900027
Category : Medical
Languages : en
Pages : 6344
Book Description
Cancer: New Insights for the Healthcare Professional: 2011 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Cancer. The editors have built Cancer: New Insights for the Healthcare Professional: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Cancer in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Cancer: New Insights for the Healthcare Professional: 2011 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.
Publisher: ScholarlyEditions
ISBN: 1464900027
Category : Medical
Languages : en
Pages : 6344
Book Description
Cancer: New Insights for the Healthcare Professional: 2011 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Cancer. The editors have built Cancer: New Insights for the Healthcare Professional: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Cancer in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Cancer: New Insights for the Healthcare Professional: 2011 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.
Antibody-Drug Conjugates and Immunotoxins
Author: Gail Lewis Phillips
Publisher: Springer Science & Business Media
ISBN: 1461454565
Category : Medical
Languages : en
Pages : 370
Book Description
This volume gathers the leading research on antibody-drug conjugates and immunotoxins. Following a rigorous overview, the volume delves into focused sections on all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.
Publisher: Springer Science & Business Media
ISBN: 1461454565
Category : Medical
Languages : en
Pages : 370
Book Description
This volume gathers the leading research on antibody-drug conjugates and immunotoxins. Following a rigorous overview, the volume delves into focused sections on all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.
Precision Medicine in Oncology
Author: Bulent Aydogan
Publisher: John Wiley & Sons
ISBN: 1119432448
Category : Medical
Languages : en
Pages : 288
Book Description
A FRESH EXAMINATION OF PRECISION MEDICINE'S INCREASINGLY PROMINENT ROLE IN THE FIELD OF ONCOLOGY Precision medicine takes into account each patient's specific characteristics and requirements to arrive at treatment plans that are optimized towards the best possible outcome. As the field of oncology continues to advance, this tailored approach is becoming more and more prevalent, channelling data on genomics, proteomics, metabolomics and other areas into new and innovative methods of practice. Precision Medicine in Oncology draws together the essential research driving the field forward, providing oncology clinicians and trainees alike with an illuminating overview of the technology and thinking behind the breakthroughs currently being made. Topics covered include: Biologically-guided radiation therapy Informatics for precision medicine Molecular imaging Biomarkers for treatment assessment Big data Nanoplatforms Casting a spotlight on this emerging knowledge base and its impact upon the management of tumors, Precision Medicine in Oncology opens up new possibilities and ways of working not only for oncologists, but also for molecular biologists, radiologists, medical geneticists, and others.
Publisher: John Wiley & Sons
ISBN: 1119432448
Category : Medical
Languages : en
Pages : 288
Book Description
A FRESH EXAMINATION OF PRECISION MEDICINE'S INCREASINGLY PROMINENT ROLE IN THE FIELD OF ONCOLOGY Precision medicine takes into account each patient's specific characteristics and requirements to arrive at treatment plans that are optimized towards the best possible outcome. As the field of oncology continues to advance, this tailored approach is becoming more and more prevalent, channelling data on genomics, proteomics, metabolomics and other areas into new and innovative methods of practice. Precision Medicine in Oncology draws together the essential research driving the field forward, providing oncology clinicians and trainees alike with an illuminating overview of the technology and thinking behind the breakthroughs currently being made. Topics covered include: Biologically-guided radiation therapy Informatics for precision medicine Molecular imaging Biomarkers for treatment assessment Big data Nanoplatforms Casting a spotlight on this emerging knowledge base and its impact upon the management of tumors, Precision Medicine in Oncology opens up new possibilities and ways of working not only for oncologists, but also for molecular biologists, radiologists, medical geneticists, and others.
Monoclonal Antibodies in Cancer
Author: Stewart Sell
Publisher: Springer Science & Business Media
ISBN: 1461251761
Category : Medical
Languages : en
Pages : 440
Book Description
This represents the third volume in a series on cancer markers pub lished by the Humana Press. The first volume, published in 1980, stressed the relationship of development and cancer as reflected in the production of markers by cancer that are also produced by normal cells during fetal development. The concept that cancer represents a problem of differentiation was introduced by Barry Pierce in describing differenti ation of teratocarcinomas. Highlighted were lymphocyte markers, alphafetoprotein, carcinoembryonic antigen, ectopic hormones, enzymes and isozymes, pregnancy proteins, and fibronectin. The second volume, published in 1982 and coedited with Britta Wahren, focused on the diagnostic use of oncological markers in human cancers, which were systematically treated on an organ by organ basis. At that time, the application of monoclonal antibodies to the identification of cancer markers was still in a very preliminary stage. A general introduc tion to monoclonal antibodies to human tumor antigens was given there by William Raschke, and other authors included coverage of those mark ers then detectable by monoclonal antibodies in their chapters.
Publisher: Springer Science & Business Media
ISBN: 1461251761
Category : Medical
Languages : en
Pages : 440
Book Description
This represents the third volume in a series on cancer markers pub lished by the Humana Press. The first volume, published in 1980, stressed the relationship of development and cancer as reflected in the production of markers by cancer that are also produced by normal cells during fetal development. The concept that cancer represents a problem of differentiation was introduced by Barry Pierce in describing differenti ation of teratocarcinomas. Highlighted were lymphocyte markers, alphafetoprotein, carcinoembryonic antigen, ectopic hormones, enzymes and isozymes, pregnancy proteins, and fibronectin. The second volume, published in 1982 and coedited with Britta Wahren, focused on the diagnostic use of oncological markers in human cancers, which were systematically treated on an organ by organ basis. At that time, the application of monoclonal antibodies to the identification of cancer markers was still in a very preliminary stage. A general introduc tion to monoclonal antibodies to human tumor antigens was given there by William Raschke, and other authors included coverage of those mark ers then detectable by monoclonal antibodies in their chapters.
Targeted Nanomedicine for Breast Cancer Therapy
Author: Shivani Rai Paliwal
Publisher: Academic Press
ISBN: 0323860044
Category : Business & Economics
Languages : en
Pages : 565
Book Description
Targeted Nanomedicine for Breast Cancer Therapy provides a compilation of treatment approaches for breast cancer, including conventional receptor targeting methods and novel strategies like stimuli responsive methods and tumor micro-environment responsive strategies. This book compiles the most important information on the state-of-the-art therapeutics, including breast cancer biomarkers and design principles of bio-responsive nanosystems. Presented in two parts, sections cover basic and receptor mediated targeting approaches and examine tumor microenvironment mediated approaches. This is a useful book for pharmaceutical scientists and basic and clinical scientists working in the research area of breast cancer and drug discovery both from academics and industry.Worldwide, breast cancer is the most common cancer in women, however, breast cancer therapy is always challenging. This book aims to help researchers remain updated on the most targeted nanomedicine research available. - Highlights promising breast cancer targets to help design nanomedicines and stimuli-triggered methods for cancer imaging and treatments - Provides in-depth exploration of targeted breast cancer therapy, along with highlights to quickly understand the most important points - Explores cutting-edge research in the area of targeted nanomedicine and drug delivery, including nanotheranostics for breast cancer therapy
Publisher: Academic Press
ISBN: 0323860044
Category : Business & Economics
Languages : en
Pages : 565
Book Description
Targeted Nanomedicine for Breast Cancer Therapy provides a compilation of treatment approaches for breast cancer, including conventional receptor targeting methods and novel strategies like stimuli responsive methods and tumor micro-environment responsive strategies. This book compiles the most important information on the state-of-the-art therapeutics, including breast cancer biomarkers and design principles of bio-responsive nanosystems. Presented in two parts, sections cover basic and receptor mediated targeting approaches and examine tumor microenvironment mediated approaches. This is a useful book for pharmaceutical scientists and basic and clinical scientists working in the research area of breast cancer and drug discovery both from academics and industry.Worldwide, breast cancer is the most common cancer in women, however, breast cancer therapy is always challenging. This book aims to help researchers remain updated on the most targeted nanomedicine research available. - Highlights promising breast cancer targets to help design nanomedicines and stimuli-triggered methods for cancer imaging and treatments - Provides in-depth exploration of targeted breast cancer therapy, along with highlights to quickly understand the most important points - Explores cutting-edge research in the area of targeted nanomedicine and drug delivery, including nanotheranostics for breast cancer therapy